Answers are grounded in this paper and cite their sources.
Evaluation of formulary access for adalimumab biosimilars in Medicare shows lower access and higher costs, indicating a need for policy reforms.
We reflect on how Medicare Part D formulary design could facilitate access to biosimilars, create cost savings and motivate investment in biosimilar development. We evaluate adalimumab, a self-administered biologic for inflammatory conditions with the most approved biosimilars, including interchangeable as a case study. We find formulary access in Part D for adalimumab biosimilars is lower relative to the innovator. Moreover, when adalimumab biosimilars are on the formulary, beneficiaries typically pay coinsurance, a cost higher than a fixed copay. This is unlike generic drugs, whose coverage in most Part D formularies typically has a co-pay of $5 or less.i The US biosimilar market has been slow to grow, limiting potential cost savings. The investment required to develop and manufacture a biosimilar is larger than a generic and requires a greater return for investment, and many off-patent biologics lack a biosimilar competitor. iiThe FDA’s October 2025 effort to simplify evidence requirements for biosimilarity may reduce development costs, but without market access, financial returns from development are limited.iii Policies to encourage formularies to expand access to biosimilars in programs such as Medicare could motivate investment.
No takes yet. Share an insight, caveat, or question.
Axelsen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: